Adherent systems for viral vector production
Cell & Gene Therapy Insights 2020; 6(10), 1607–1613
Viral vectors are crucial gene delivery vehicles for cell and gene therapy purposes. This decade has witnessed advancement of clinical trials from Phase 1 to Phase 3 and regulatory approval of a few AAV and CAR-T-based therapies. In the case of gene therapy using AAV, wherein the drug product itself is a vector, the regulatory requirements are more stringent than for CAR-X cell therapies using lentiviral vector, where the vector acts as a critical raw material or gene modifying agent. Hence the demand has increased for both research grade and GMP grade viral vectors. Ease of multi-plasmid transfection, scalability, fully characterized cGMP cell lines, and single-use and closed systems for large-scale production are crucial to the production of these viral vectors. Adherent systems were classically utilized for viral vector production and are still in use.